Aims
Our aim was to prospectively assess the efficacy of the DFP-DFO vs DFX in a cohort of TM patients by quantitative MR.
Methods
Among the first 739 TM patients enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) network, 253 patients performed a MR follow up study at 18 ± 3 months according to the protocol. We evaluated prospectively the 25 patients treated with DFP-DFO versus the 44 patients treated with DFX between the 2 MR scans. Myocardial iron concentrations were measured by T2* multislice multiecho technique.
Results
Excellent/good levels of compliance were similar in the 2 groups (DFP-DFO 96% vs DFX 100%; P=0.36). At baseline the 2 groups were homogeneous for cardiac iron. Among the patients with no significant myocardial iron overload (MIO) at baseline (global heart T2* ≥ 20 ms), there were no significant differences between groups to maintain the patients without myocardial iron overload (DFP-DFO 95% vs DFX 96%; P =1.0). Among the patients with MIO at baseline (global heart T2* < 20 ms), only in the DFX group there was a significant improvement in the global heart T2* value (11 ± 5 ms at baseline versus 16 ± 8 at 18 ± 3 months, P=0.0001) and in the number of segment with a normal T2* value (P=0.003). The improvement in the global heart T2* was not significantly different in the DFP-DFO versus the DFX group (mean difference global heart T2* 2.2 ± 4.1 ms versus 4.6 ± 4.8 P=0.2). Conclusions: Prospectively in the clinical setting over 15 months we did not find significant differences on cardiac iron by quantitative MRI in TM patients treated with sequential DFP-DFO versus the TM patients treated with DFX.
